Dietary fiber prevents obesity-related liver lipotoxicity by modulating sterol-regulatory element binding protein pathway in C57BL/6J mice fed a high-fat/cholesterol diet

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Han, Shufen ^a   Jiao, Jun ^a   Zhang, Wei ^a   Xu, Jiaying ^b   Wan, Zhongxiao ^a   Zhang, Weiguo ^c   Gao, Xiaoran ^c   Qin, Liqiang ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CHOLESTEROL; FAT INTAKE; FATTY ACID SYNTHASE; LIVER X RECEPTOR; NR1H3 PROTEIN, HUMAN; NR1H3 PROTEIN, MOUSE; ORPHAN NUCLEAR RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DIETARY FIBER; DRUG EFFECTS; DYSLIPIDEMIAS; FAT INTAKE; INSULIN RESISTANCE; LIPOGENESIS; MALE; METABOLISM; MOUSE; PHARMACOLOGY;

ACETYL-COA CARBOXYLASE; ANIMALS; CHOLESTEROL; DIETARY FATS; DIETARY FIBER; DYSLIPIDEMIAS; FATTY ACID SYNTHASE, TYPE I; INSULIN RESISTANCE; LIPOGENESIS; LIVER X RECEPTORS; MALE; MICE; ORPHAN NUCLEAR RECEPTORS; PPAR ALPHA; PPAR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84946118314     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15256     Document Type: Article

References (47)

1. Zalesin, K. C. et al. Impact of obesity on cardiovascular disease. Med. Clin. North. Am. 95, 919-937 (2011).
2. Wang, Y. C. et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 378, 815-825 (2011).
3. Cusi, K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 142, 711-25 (2012).
4. Schaffer, J. E. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol. 14, 281-287 (2003).
5. Unger, R. H., Clark, G. O., Scherer, P. E. and Orci, L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim. Biophy. Acta. 1801, 209-214 (2010).
6. Kotzka, J. and Muller-Wieland, D. Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert. Opin. Ther. Targets. 8, 141-149 (2004).
7. Yoon, M. The role of PPARalpha in lipid metabolism and obesity: focusingon the effects of estrogen on PPARalpha actions. Pharmacol. Res. 60, 151-159 (2009).
8. Threapleton, D. E. et al. Dietary fiber intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ (2013) Available at doi: 10.1136/bmj.f6879. (Accessed : 19th December 2013).
9. Galistero, M., Duarte, J. and Zarzuelo, A. Effects of dietary fibers on disturbances clustered in the metablic syndrome. J. Nutr. Biochem. 19, 71-84 (2008).
10. Anderson, J. W. et al. Health benefits of dietary fiber. Nutr. Rev. 67, 188-205 (2009).
11. Wanders, A. J. et al. Effects of dietary fibre on subjective appetite, energy intake and body weight: a systematic review of randomized controlled trials. Obes. Rev. 12, 724-739 (2011).
12. Adam, C. L. et al. Different types of soluble fermentable dietary fibre descrease food intake, body weight gain and adiposity in young adult male rats. Nutr. Metab (2014) (Accessed: 14 August 2014).
13. Raninen, K., Lappi, J., Mykkanen, H. and Poutanen, K. Dietary fiber type reflects physiological functionality: comparison of grain fiber, inulin, and polydextrose. Nutr. Rev. 69, 9-21 (2011).
14. Schulze, M. B. et al. Fiber and magnesium intake and incidence of type 2 diabetes, a prospective study and meta-analysis. Arch. Intern. Med. 167, 956-965 (2007).
15. Gemen, R., de Vries, J. F. and Slavin, J. L. Relationship between molecular structure of cereal dietary fiber and health effects: focus on glucose/insulin response and gut health. Nut. Rev. 69, 22-33 (2011).
16. Immerstrand, T. et al. Effects of oat bran, processed to different molecular weights of beta-glucan, on plasma lipids and caecal formation of SCFA in mice. Br. J. Nutr. 104, 364-373 (2010).
17. Kritchevsky, D. and Story, J. A. Binding of bile salts in vitro by nonnutritive fiber. J. Nutr. 104, 458-462 (1974).
18. McIntosh, G. H. Noakes, M. Royle, P. J. and Foster, P. R. Whole-grain rye and wheat foods and markers of bowel health in overweight middle-aged men. Am. J. Clin. Nutr. 77, 967-974 (2003).
19. Kaczmarczyk, M. M., Miller, M. J. and Freund, G. G. The health benefits of dietary fiber: Beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metabolism. 61, 1058-1066 (2012).
20. Paglialunga, S., Ludzki, A., Root-McCaig, J. and Holloway, G. P. In adipose tissue, increased mitochondrial emission of reactive oxygen species is important for short-term high-fat diet-induced insulin resistance in mice. Diabetologia. 58, 1071-1080 (2015).
21. Jadeja, R. N., Thounaojam, M. C., Dandekar, D. S., Devkar, R. V. and Ramachandran, A. V. Clerodendron glandulosum.Coleb extract ameliorates high fat diet/fatty acid induced lipotoxicity in experimental models of non-alcoholic steatohepatitis. Food. Chem/Toxicol. 48, 3424-3431 (2010).
22. Abdurrachim, D. et al. Cardiac diastolic dysfunction in high-fat diet fed mice is associated with lipotoxicity without impairment of cardiac energetics in vivo. Biochim. Biophys. Acta. 1842, 1525-1537 (2014).
23. Jimenez-Cruz, A., Loustaunau-Lopez, V. M. and Bacardi-Gascon, M. The use of low glycemic and high satiety index food dishes in Mexico: a low cost approach to prevent and control obesity and diabetes. Nutr. Hospital. 21, 353-356 (2006).
24. Behall, K. M. Dietary fiber: nutritional lessons for macronutrient substitutes. Ann. N. Y. Acad. Sci. 819, 142-154 (1997).
25. Aleixandre, A. and Miguel, M. Dietary fiber in the prevention and treatment of metabolic syndrome: a review. Crit. Rev. Food. Sci. Nutr. 48, 905-912 (2008).
26. Lairon, D. Dietary fiber and control of body weight. Nutr. Metab. Cardiovasc. Dis. 17, 1-5 (2007).
27. Cheng, H. H. and Lai, M. H. Fermentation of resistant rice starch produces propionate reduced serum and hepatic cholesterol in rats. J. Nutr. 130, 1991-1995 (2000).
28. Brown, L., Rosner, B., Willett, W. W. and Sacks, F. M. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am. J. Clin. Nutr. 69, 30-42 (1999).
29. Babio, N., Balanza, R., Basulto, J., Bullo, M. and Salas-Salvado, J. Dietary fiber: influence on body weight, glycemic control and plasma cholesterol profile. Nutr. Hosp. 25, 327-340, (2010).
30. Unger, R. H. and Orci, L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB. J. 15, 312-321 (2001).
31. Van Herpen, N. A. and Schrauwen-Hinderling, V. B. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol. Behav. 94, 231-241 (2008).
32. Kotronen, A., Westerbacka, J., Bergholm, R., Pietilainen, K. H. and Yki-Jarvinen, H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 92, 3490-3497 (2007).
33. Lionetti, L. et al. From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr. Metab. Cardiovasc. Dis. 21, 222-230 (2011).
34. Slavin, J. L. Dietary fiber and body weight. Nutrition. 21, 411-418 (2005).
35. Horton, J. D., Goldstein, J. L. and Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the river. J. Clin. Invest. 109, 1125-1131 (2002).
36. Daemen, S. and Kutmon, M. A pathway apporch to investigate the function and regulation of SREBPs. Genes. Nutr. 8, 289-300 (2013).
37. Sato, R. Sterol metabolism and SREBP activation. Arch. Biochem. Biophys. 501, 177-181 (2010).
38. Ahmed, M. H. and Byrne, C. D. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug. Discov. Today. 12, 740-747 (2007).
39. Repa, J. J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol, LXRalpha and LXRbeta. Genes. Dev. 14, 2819-2830 (2000).
40. Schultz, J. R. et al. Role of LXRs in control of lipogenesis. Genes. Dev. 14, 2831-2838 (2002).
41. Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307 (2006).
42. Kersten, S. Integrated physiology and systems biology of PPARα . Mol. Metab. 3, 354-371 (2014).
43. Lehrke, M. and Lazar, M. A. The many faces of PPARγ . Cell. 123, 993-999 (2005).
44. Inoue, M. et al. Increased expression of PPARγ in high fat diet-induced liver steatosis in mice. Biochem. Biophys. Res. Commun. 336, 215-222 (2005).
45. Ip, E., Farrell, G., Hall, P., Robertson, G. and Leclercq, I. Administration of the potent PPARα agonist,Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 39, 1286-1296 (2004).
46. Osman, O. S. et al. A novel automated image analysis method for accurate adipocyte quantification. Adipocyte. 2, 160-164 (2013).
47. Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28, 412-419.